Press release

Revitalising renal care: Diaverum at ERA/EDTA 2013 in Istanbul
Renal care provider presents service portfolio at European event and results of ORAL-D study

Munich / Istanbul, 17 May 2013 – Diaverum, one of the world’s leading renal care service providers, is presenting its service portfolio and the results of its latest research at the ERA/EDTA 2013. The company provides renal care to 22,000 patients in 265 kidney centres in 18 countries across Europe, Middle East, Latin America and Australia. The European Renal Association - European Dialysis and Transplant Association is one of the fastest growing medical associations with the aim to encourage and to report advances in the field of clinical nephrology, dialysis, renal transplantation and related subjects.

“The ERA/EDTA is a must for us as a global player. Europe is our strongest market in which we are growing rapidly both through acquisitions and the expansion of our service offering,” said Dag Andersson, CEO and President of Diaverum. “Meeting with international healthcare companies and the best physicians worldwide is very important for us on our way to becoming an integrated renal patient care provider.”

Christina Sterner, Chief Communications Officer at Diaverum, explained that at Diaverum the patients are “at the heart” of everything we do. “We care for our patients, both from a physical as well as an emotional point of view, and this is what we would like to show with our presence at the exhibition.”

With ‘Revitalising renal care’, Diaverum is positioning itself as an interesting partner and excellent employer. “Our aim is to provide our patients with a warm and friendly atmosphere when visiting our clinics, and when leaving we hope they feel revitalised,” said Sterner.

Diaverum will also present the preliminary results of ongoing scientific studies in the poster sessions at ERA/EDTA 2013. Professor Giovanni FM Strippoli, SVP Scientific Affairs at Diaverum, explained that the Diaverum scientific research agenda is based on the “needs and demands” of the patients, using a full array of epidemiology study designs including systematic reviews, cohort studies, qualitative research methods and other.

“Patients demand and deserve research on prevention, complications and symptoms, and particularly research that takes into consideration psychological factors as well as the well being of the entire body,” Prof. Strippoli added.

The majority of the Diaverum posters at ERA/EDTA 2013 are focusing on the ORAL-D study, a multinational study, the largest worldwide, prospective cohort in design, exploring oral diseases in people on haemodialysis.

“This study looks at the prevalence of dental, periodontal, oral mucosa and salivary gland abnormalities as well as oral hygiene habits in people on haemodialysis,” explained Prof. Strippoli. “Data on a study of correlates of depression in end-stage kidney disease and correlates of patient satisfaction from dialysis treatment will also be presented. All in all, this talks about high engagement and social responsibility by Diaverum staff in participating kidney centres, of which I am extremely proud.”

The following posters will be presented:

Sunday, May 19, 2013

- “Thirst and oral symptoms in people on hemodialysis: a multinational prospective cohort study (oral-d)” (no SP581)
- “Periodontal disease and all cause and cardiovascular mortality in hemodialysis patients: a prospective multinational cohort study” (no SP580)
- “Oral disease in people with chronic kidney disease: a systematic review and meta-analysis of cohort studies” (no SP605)
- “Oral hygiene habits in people on hemodialysis: a multinational prospective cohort study (oral-d)” (no SP590)
• “Dental health and all cause and cardiovascular mortality in hemodialysis patients: a prospective multinational cohort study” (no SP618)

Monday, May 20, 2013
• “Patient satisfaction of different aspects of long-term haemodialysis care: a multinational cross-sectional survey of patients” (no MP572)
• “Depression in patients requiring hemodialysis: prevalence, correlates and association with mortality in a large multi-national cohort study” (no MP562)
• “Prevalence of oral lesions in hemodialysis patients: the oral-d prospective multinational cohort study” (no MP581)

The Diaverum booth is situated on level B5 in the Istanbul Congress Center, booth number O16. The exhibition starts on Saturday, 18 May at 17:00 and ends on Tuesday, 21 May at 12.00. Visitors are welcome to learn more about Diaverum and to meet the Diaverum experts and the top management team.

Press Contact
Christina Sterner,
Chief Communication Officer
Diaverum
E-mail: Christina.sterner@diaverum.com and research@diaverum.com
Phone: +46 767 66 90 67

About Diaverum
At Diaverum, our mission is to improve the quality of life for renal patients by revitalising them both physically and emotionally. Being one of the world’s leading renal care providers, Diaverum offers a holistic approach, from preventive and early stage renal care to all renal replacement therapies. As a product independent provider — the largest in Europe — we are able to focus solely on caring for the individual needs of our patients. Our experience in renal care dates back 20 years, when the first dialysis clinic was established, previously under our former name Gambro Healthcare. Today, 7,100 employees care for almost 22,000 patients in 18 countries in Europe, Latin America, Middle East and Australia. Diaverum has its roots in Lund, Sweden and a corporate office located in Munich, Germany. For more information visit: www.diaverum.com.